Arellano, M., Thirman, M., DiPersio, J., Heiblig, M., Stein, E., Schuh, A., Zucenka, A., Botton, S. D., Grove, C., Mannis, G., Papayannidis, C., Perl, A., Issa, G., Aldoss, I., Bajel, A., Dickens, D., Kuhn, M., Mantzaris, I., Raffoux, E., Traer, E., Amitai, I., Döhner, H., Greco, C., Kovacsovics, T., McMahon, C., Montesinos, P., Pigneux, A., Shami, P., Stone, R., Wolach, O., Harpel, J., Chudnovsky, Y., Yu, L., Bagley, R., Smith, A. R., Blachly, J. (2025). Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study. Blood. https://doi.org/10.1182/blood-2025-3418